decisionhealth Newsletters, Answer Books - 2009 Issue 2 (February)
Chemotherapy / Oral anti-nausea drugs as part of cancer chemotherapeutic regimen
Subscribe or sign in to view the full article.
Article Overview
This article explains Medicare coverage for oral anti-emetic drugs when they are used as part of a cancer chemotherapy regimen. It outlines the general coverage framework, timing and ordering requirements, billing and claims submission considerations, and the role of DMERCs and other Medicare billing pathways. The article is intended for coding, billing, and reimbursement professionals who need to understand how this category of pharmacy-related chemotherapy support is handled under Medicare Part B.
Why This Topic Matters
Understanding this guidance helps providers and billers determine whether oral anti-emetic drug claims fit within Medicare coverage for chemotherapy-related treatment and how those claims should be documented and routed.
What You Will Learn
- How Medicare describes coverage for oral anti-emetic drugs in connection with cancer chemotherapy
- What general timing and ordering documentation is discussed for this benefit
- How claims submission and billing responsibility are addressed for these drugs
- Which kinds of Medicare payment and processing entities are mentioned in the guidance
Who Should Read This
- Medical coders
- Billing specialists
- Revenue cycle staff
- Pharmacy billing staff
- Oncology practice administrators
Code Ranges Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com